granisetron has been researched along with Dyskinesia, Drug-Induced in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C | 1 |
| Alberts, VA; Catalano, G; Poole, MA | 1 |
2 other study(ies) available for granisetron and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Granisetron; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists | 2021 |
Tardive dyskinesia as a result of long-term prochlorperazine use.
Topics: Antiemetics; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Granisetron; Humans; Middle Aged; Nausea; Ondansetron; Prochlorperazine; Time Factors; Vomiting | 1996 |